ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "Bortezomib"

  • Abstract Number: 97 • Pediatric Rheumatology Symposium 2017

    Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis

    Renee F Modica1, Kathleen M Vazzana2, Natalie Jane Shiff3, Akaluck Thatayatikom3 and Melissa E Elder1, 1Department of Pediatrics, University of Florida, Gainesville, FL, 2Pediatrics, University of Florida at Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, 3Pediatrics, University of Florida, Gainesville, FL

    Background/Purpose:  Neuropsychiatric systemic lupus erythematosus (NPSLE) with psychosis is challenging to treat with refractory cases often requiring prolonged hospitalization due to significant functional impairment and…
  • Abstract Number: 2782 • ACR/ARHP Annual Meeting 2016

    Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems

    Kazuhisa Nozawa1, Yuko Matsuki2, Ken Yamaji3, Naoto Tamura4 and Yoshinari Takasaki3, 12-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, 2Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 4Rheumatology, Juntendo University, Tokyo, Japan

    Background/Purpose:   Lupus nephritis (LN) is one of the main causes of morbidity and mortality in SLE. Although a combination therapy using steroids and immunosuppressant…
  • Abstract Number: 1812 • ACR/ARHP Annual Meeting 2015

    The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus

    Tomonori Ishii1, Yoshiya Tanaka2, Atsushi Kawakami3, Kazuyoshi Saito2, Kunihiro Ichinose4, Yuko Shirota5, Hiroshi Fujii5, Yoko Fujita6, Yukiko Kamogawa5, Tomoaki Machiyama5, Kanae Akita5 and Hideo Harigae5, 1Department of Clinical Trial Implementation, Tohoku University Hospital, Clinical Research, Innovation and Education Center, Sendai, Japan, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 3Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 6Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan

    Background/Purpose: Systemic lupus erythematosus (SLE) is a disease characterized by production and deposition of anti-dsDNA antibody. In recent years, treatment methods targeting antibody-producing B cell…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology